Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...
Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous AdministrationKey ...
Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...
India, March 13 -- Allergic rhinitis, often called hay fever, affects hundreds of millions of people worldwide and commonly ...
Investor's Business Daily on MSN
Dianthus Therapeutics has appreciated 12-fold over two years. What's going on?
Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
Ketogenic diet therapies, including the classic ketogenic diet, modified Atkins diet, and low glycaemic index treatment, have ...
Learn how targeted-release budesonide treats IgA nephropathy, cutting proteinuria and slowing GFR decline with fewer steroid side effects. When are you utilizing endothelin antagonists, complement ...
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...
Autoimmune and autoinflammatory diseases arise from complex interactions between host genetic susceptibility and environmental factors, particularly the gut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results